---
kind: "section"
citation: "21 U.S.C. § 1714"
title: "21"
title_heading: "Food and Drugs"
number: "1714"
heading: "Awards for demonstration programs by local partnerships to coerce abstinence in chronic hard-drug users under community supervision through the use of drug testing and sanctions"
release: "119-102"
date: "2026-07-12"
url: "https://uscodex.org/usc/21/1714"
units:
  - "Chapter 22 — National Drug Control Policy"
---

# §1714. Awards for demonstration programs by local partnerships to coerce abstinence in chronic hard-drug users under community supervision through the use of drug testing and sanctions

- (a) **Awards required—** The [Director](/usc/21/1701.md?p=4) shall make competitive awards to fund demonstration programs by eligible partnerships for the purpose of reducing the use of [illicit drugs](/usc/21/1701.md?p=8) by chronic hard-[drug](/usc/21/1701.md?p=5) users living in the community while under the supervision of the criminal justice system.
- (b) **Use of award amounts—** Award amounts received under this section shall be used—
  - (1) to support the efforts of the [agencies](/usc/21/1701.md?p=1), organizations, and researchers included in the eligible partnership;
  - (2) to develop and field a [drug](/usc/21/1701.md?p=5) testing and graduated sanctions program for chronic hard-[drug](/usc/21/1701.md?p=5) users living in the community under criminal justice supervision; and
  - (3) to assist individuals described in [subsection (a)](#a) by strengthening rehabilitation efforts through such means as job training, [drug](/usc/21/1701.md?p=5) treatment, or other services.
- (c) **Eligible partnership defined—** In this section, the term “eligible partnership” means a working group whose application to the [Director](/usc/21/1701.md?p=4)—
  - (1) identifies the roles played, and certifies the involvement of, two or more [agencies](/usc/21/1701.md?p=1) or organizations, which may include—
    - (A) State, local, or tribal [agencies](/usc/21/1701.md?p=1) (such as those carrying out police, probation, prosecution, courts, corrections, parole, or treatment functions);
    - (B) Federal [agencies](/usc/21/1701.md?p=1) (such as the [Drug](/usc/21/1701.md?p=5) Enforcement [Agency](/usc/21/1701.md?p=1), the Bureau of Alcohol, Tobacco, Firearms, and Explosives, and United States Attorney [offices](/usc/21/1701.md?p=14)); and
    - (C) community-based organizations;
  - (2) includes a qualified researcher;
  - (3) includes a plan for using judicial or other criminal justice authority to administer [drug](/usc/21/1701.md?p=5) tests to individuals described in [subsection (a)](#a) at least twice a week, and to swiftly and certainly impose a known set of graduated sanctions for non-compliance with community-release provisions relating to [drug](/usc/21/1701.md?p=5) abstinence (whether imposed as a pre-trial, probation, or parole condition or otherwise);
  - (4) includes a [strategy](/usc/21/1701.md?p=12) for responding to a range of substance use and abuse problems and a range of criminal histories;
  - (5) includes a plan for integrating data infrastructure among the [agencies](/usc/21/1701.md?p=1) and organizations included in the eligible partnership to enable seamless, real-time tracking of individuals described in [subsection (a)](#a);
  - (6) includes a plan to monitor and measure the progress toward reducing the percentage of the population of individuals described in [subsection (a)](#a) who, upon being summoned for a [drug](/usc/21/1701.md?p=5) test, either fail to show up or who test positive for [drugs](/usc/21/1701.md?p=5).
- (d) **Reports to Congress—**
  - (1) **Interim report—** Not later than June 1, 2009, the [Director](/usc/21/1701.md?p=4) shall submit to Congress a report that identifies the best practices in reducing the use of [illicit drugs](/usc/21/1701.md?p=8) by chronic hard-[drug](/usc/21/1701.md?p=5) users, including the best practices identified through the activities funded under this section.
  - (2) **Final report—** Not later than June 1, 2010, the [Director](/usc/21/1701.md?p=4) shall submit to Congress a report on the demonstration programs funded under this section, including on the matters specified in [paragraph (1)](#d-1).
- (e) **Authorization of appropriations—** There is authorized to be appropriated to carry out this section $4,900,000 for each of fiscal years 2007 through 2009.

## Source credit

(Pub. L. 105–277, div. C, title VII, § 716, as added Pub. L. 109–469, title XI, § 1119, Dec. 29, 2006, 120 Stat. 3547; amended Pub. L. 105–277, div. C. title VII, § 715, Oct. 21, 1998, 112 Stat. 2681–693; Pub. L. 109–469, title VI, § 602, Dec. 29, 2006, 120 Stat. 3533; Pub. L. 115–271, title VIII, § 8202(a), (b)(2), Oct. 24, 2018, 132 Stat. 4110.)

## Notes

### Editorial Notes

### Amendments

2018—Pub. L. 115–271, § 8202(b)(2), repealed Pub. L. 105–277, § 715. See 1998 Amendment note below.

Pub. L. 115–271, § 8202(a), revived and restored this section as in effect on Sept. 29, 2003, and as amended by Pub. L. 109–469 and Pub. L. 112–166. See Reauthorization of the Office of National Drug Control Policy note set out under section 1701 of this title.

2006—Pub. L. 109–469 amended Pub. L. 105–277, § 715, which provided for the repeal of this section. See 1998 Amendment note below.

1998—Pub. L. 105–277, § 715, as amended by Pub. L. 109–469, § 602, which provided for the repeal of this section effective Sept. 30, 2010, was repealed by Pub. L. 115–271, § 8202(b)(2). See former section 1712 of this title.